Navigation Links
Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers
Date:6/1/2009

ical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains forward-looking statements, including, but not limited to, statements related to the potential efficacy and therapeutic uses of R788, Rigel's plans to pursue clinical development of R788, and the timing of results thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "may" "believes," "expects" and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on the company's current expectations
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Advancements in Integrative Medicine Research to Be Evaluated by Scientists From Leading International Academic Health Centers
2. MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa
3. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
4. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
5. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
6. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
7. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
8. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
9. National Medical Interpreter Certification Testing Enters Pilot Phase
10. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
11. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... of New England and the Rhode Island House and senate ... multiple sclerosis, AIDS and other chronic // diseases ... these patients. The new bill allows patients to have possession ... marijuana was illegal. But, the Governor Carcieri still oppose the ...
... has a counter which states that heart conditions became worse ... heart disease when they were fed a soy diet. ... mice carried and were severely affected by the soy diet. ... failure. This study was done by University of Colorado at ...
... a pilot study by The New Women's Health Initiative ... fat but rich in carbohydrates results in negligible weight ... between weight alterations in postmenopausal women Vis a Vis ... in this category were advised to reduce the fat ...
... was misled about the dangers of taking cannabis when the ... than a year ago, the British Home Secretary admits today. ... decision taken by his predecessor, David Blunkett, Charles Clarke said ... link between cannabis and mental illness. He made these damning ...
... in the offing for abdominal aortic aneurysm, a blood vessel condition ... ,This condition, a swelling // in the ... bursts, accounts for 1.36% of deaths in men over 65 in ... for men in that age group, Pulse magazine says. ...
... customers to trap doctors who conduct sex determination tests for ... State’s sex ratio is less than 800 females for every ... would be paid up to Rs.5,000 to help nab diagnostic ... Family Welfare Secretary D.S. Guru said field officers of the ...
Cached Medicine News:Health News:UK public misled over downgrading cannabis: Govt 2Health News:Experts urging artery screening in the UK 2
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 25, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ... John H. Johnson as Chief Executive Officer, effective January 31, ... Savient,s board of directors. Mr. Johnson brings significant ... a Senior Vice President of Eli Lilly and Company and ...
... recently launched eCS Inpatient EHR V1.2 (eCS), the first ... medium hospitals. eCS,s uniqueness is the tight linkage of ... a single web-based software solution. The solution is offered ... simplified deployment. "eCS is an affordable solution ...
Cached Medicine Technology:Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 2Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 3Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 4eCareSoft Launches Comprehensive EHR for Small & Medium Hospitals 2
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
... For use as a ... detecting IgG antibody to Toxoplasma ... to rubella virus (rubella IgG), ... IgG) and IgG antibody to ...
... VITROS Anti-HCV assay is the third diagnostic,hepatitis ... Drug,Administration capable of being run in a ... with Intellicheck. Now the laboratory staff,can run ... of more than 27 assays, and provide ...
... For use as a quality ... immunoglobulin M (IgM) antibodies to ... IgM), IgM antibodies to hepatitis ... B e antigen (HBeAg) and ...
Medicine Products: